Browse LSR

Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass membrane protein
Domain PF05624 Lipolysis stimulated receptor (LSR)
Function

Probable role in the clearance of triglyceride-rich lipoprotein from blood. Binds chylomicrons, LDL and VLDL in presence of free fatty acids and allows their subsequent uptake in the cells (By similarity).

> Gene Ontology
 
Biological Process GO:0001889 liver development
GO:0007043 cell-cell junction assembly
GO:0019216 regulation of lipid metabolic process
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0045216 cell-cell junction organization
GO:0048732 gland development
GO:0060856 establishment of blood-brain barrier
GO:0061008 hepaticobiliary system development
GO:1904274 tricellular tight junction assembly
Molecular Function -
Cellular Component GO:0032994 protein-lipid complex
GO:0034358 plasma lipoprotein particle
GO:0034361 very-low-density lipoprotein particle
GO:0034362 low-density lipoprotein particle
GO:0034385 triglyceride-rich lipoprotein particle
GO:0042627 chylomicron
GO:0061689 tricellular tight junction
GO:0070160 occluding junction
GO:1990777 lipoprotein particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-171052: LDL-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-8855121: VLDL interactions
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LSR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LSR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LSR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.4690.0155
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.3030.423
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.5950.182
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6890.126
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9220.738
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3940.91
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1930.723
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7980.427
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6260.613
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.6430.705
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.0670.673
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1310.302
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LSR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LSR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LSR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LSR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LSR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LSR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LSR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLSR
Namelipolysis stimulated lipoprotein receptor
Aliases LISCH7; ILDR3; lipolysis-stimulated remnant; immunoglobulin-like domain containing receptor 3; LISCH protein ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LSR collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.